Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Rein Therapeutics (RNTX) Return on Capital Employed (2017 - 2025)

Rein Therapeutics filings provide 9 years of Return on Capital Employed readings, the most recent being 0.32% for Q4 2025.

  • For the quarter ending Q4 2025, Return on Capital Employed fell 15.0% year-over-year to 0.32%, compared with a TTM value of 0.32% through Dec 2025, down 15.0%, and an annual FY2025 reading of 0.29%, down 11.0% over the prior year.
  • Return on Capital Employed hit 0.32% in Q4 2025 for Rein Therapeutics, down from 0.18% in the prior quarter.
  • The five-year high for Return on Capital Employed was 0.17% in Q4 2024, with the low at 1.45% in Q1 2023.
  • Median Return on Capital Employed over the past 5 years was 0.42% (2021), compared with a mean of 0.6%.
  • The sharpest move saw Return on Capital Employed tumbled -75bps in 2023, then surged 126bps in 2024.
  • Year by year, Return on Capital Employed stood at 0.56% in 2021, then tumbled by -131bps to 1.3% in 2022, then skyrocketed by 77bps to 0.3% in 2023, then soared by 41bps to 0.17% in 2024, then plummeted by -86bps to 0.32% in 2025.
  • According to Business Quant data, Return on Capital Employed over the past three periods came in at 0.32%, 0.18%, and 0.2% for Q4 2025, Q3 2025, and Q2 2025 respectively.